Related Experiment Video
Updated: May 17, 2026

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
Published on: March 21, 2025
Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein
1Wallingford, Connecticut, United States of America. sgallion@comcast.net
Abstract:
Soluble amyloid beta (Aβ) peptide has been linked to the pathology of Alzheimer's disease. A variety of soluble oligomers have been observed to be toxic, ranging from dimers to protofibrils. No tertiary structure has been identified as a single biologically relevant form, though many models are comprised of highly ordered β-sheets. Evidence exists for much less ordered toxic oligomers. The mechanism of toxicity remains highly debated and probably involves multiple pathways. Interaction of Aβ oligomers with the N-terminus of the cellular form of the prion protein (PrP(c)) has recently been proposed. The intrinsically disordered nature of this protein and the highly polymorphic nature of Aβ oligomers make structural resolution of the complex exceptionally challenging. In this study, molecular dynamics simulations are performed for dodecameric assemblies of Aβ comprised of monomers having a single, short antiparallel β-hairpin at the C-terminus. The resulting models, devoid of any intermolecular hydrogen bonds, are shown to correlate well with experimental data and are found to be quite stable within the hydrophobic core, whereas the α-helical N-termini transform to a random coil state. This indicates that highly ordered assemblies are not required for stability and less ordered oligomers are a viable component in the population of soluble oligomers. In addition, a tentative model is proposed for the association of Aβ dimers with a double deletion mutant of the intrinsically disordered N-terminus of PrP(c). This may be useful as a conceptual working model for the binding of higher order oligomers and in the design of further experiments.
Insights
Soluble amyloid beta (Aβ) oligomers, implicated in Alzheimer's disease, can be less ordered and still stable. Molecular dynamics simulations suggest these less ordered forms are viable and may interact with the prion protein (PrP(c)).
Area of Science:
- Neuroscience
- Biochemistry
- Computational Biology
Background:
- Soluble amyloid beta (Aβ) oligomers are linked to Alzheimer's disease pathology.
- The exact toxic structure of Aβ oligomers remains unclear, with evidence for both ordered and disordered forms.
- The interaction between Aβ oligomers and the cellular prion protein (PrP(c)) is a recent area of investigation.
Purpose of the Study:
- To investigate the structural stability and characteristics of dodecameric Aβ assemblies using molecular dynamics simulations.
- To explore the potential role of less ordered Aβ oligomers in Alzheimer's disease.
- To propose a model for the interaction between Aβ dimers and a PrP(c) N-terminal mutant.
Main Methods:
- Molecular dynamics simulations of dodecameric Aβ assemblies with specific monomeric structures.
- Analysis of structural stability, intermolecular interactions, and conformational changes.
- Development of a tentative model for Aβ dimer binding to a PrP(c) mutant.
Main Results:
- Aβ assemblies with antiparallel β-hairpins at the C-terminus, lacking intermolecular hydrogen bonds, demonstrated stability.
- The N-termini of Aβ monomers adopted a random coil state, indicating less ordered structures are stable.
- A model for Aβ dimer interaction with the N-terminus of PrP(c) was proposed.
Conclusions:
- Highly ordered assemblies are not essential for Aβ oligomer stability; less ordered forms are viable in solution.
- The findings support the role of less ordered Aβ oligomers in Alzheimer's disease pathogenesis.
- The proposed Aβ-PrP(c) interaction model may guide future research and experimental design.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

